Plaque Psoriasis

In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.

These data on patients in Japan demonstrate positive efficacy and safety findings in real-world settings, with uniquely positive results among bio-naïve patients.

In this analysis, links between psoriasis and metabolic and cardiovascular risk were evaluated along with correlations between biomarkers and severity.

This analysis highlights the increased risk among those with psoriasis for developing such ocular conditions as conjunctivitis, dry eye, and conjunctival hyperemia.

These data highlight the comparability of Humira, the adalimumab originator, to the drug’s biosimilars in terms of efficacy in treating psoriasis.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

These data highlight the long-term maintenance of bimekizumab responses among individuals with psoriasis, looking at bio-naïve and bio-switched patients.

Investigators highlight systemic treatments for psoriatic disease that maintain lower rates of serious infections among older adults suffering from psoriatic disease.

These data highlight the potential benefit of continuous treatment with subcutaneous spesolimab for generalized pustular psoriasis (GPP).

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

This interview with Yamauchi highlights phase 3b findings on tildrakizumab among patients with moderate-to-severe nail psoriasis.

Andrew Alexis, MD, MPH, highlights his ‘What’s New’ talk at AAD 2025 on new practices for treating pigmentary disorders such as vitiligo.

This interview with Melinda Gooderham, MD, covers recent findings from the phase 3 ARRECTOR trial on roflumilast foam 0.3% in scalp and body psoriasis.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

Robert Bissonnette, MD, discusses data from the ICONIC-LEAD trial and the potential role of icotrokinra in plaque psoriasis.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

These data highlight deucravacitinib’s impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

This review of January 2025 in dermatology news highlights new developments in the treatment of conditions such as psoriasis, alopecia areata, and atopic dermatitis.